Zhejiang Medicine Co., Ltd. (600216.SS) announced a profit for first quarter that Dropped, from last year
The company's bottom line came in at RMB287.012 million, or RMB0.30 per share. This compares with RMB409.085 million, or RMB0.43 per share, last year.
The company's revenue for the period fell 2.9% to RMB2.190 billion from RMB2.255 billion last year.
Zhejiang Medicine Co., Ltd. earnings at a glance (GAAP) :
-Earnings: RMB287.012 Mln. vs. RMB409.085 Mln. last year.-EPS: RMB0.30 vs. RMB0.43 last year.-Revenue: RMB2.190 Bln vs. RMB2.255 Bln last year.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.